• 1
    CDC Morbidity and Mortality Weekly Report. Prevention of hepatitis A through active and passive immunization. Recommendation of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 1996; 45( RR-15): 130.
  • 2
    Centers for Disease Control and Prevention. Recommended immunization schedules for person aged 0 through 18 years — United States, 009. MMWR. 2008; 57: 5152.
  • 3
    AAP Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics. 2007; 1: 189199.
  • 4
  • 5
    Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: HollingerFB, LemonSM, MargolisH. Viral hepatitis and liver disease. Philadelphia: Williams & Wilkins. 1991; 1420.
  • 6
    Janaszek-Seydlitz W, Bucholc B, Slusarczyk J, et al. The epidemiology of hepatitis A in Poland: prevalence of hepatitis A antibodies in population. 16th European Congress of Clinical Microbiology and Infectious Diseases Nice, France, April 1–4 2006. Abstract p 783.
  • 7
    Winesett M. Inflammatory bowel disease in children and adolescents. Pediatr Ann. 1997; 26: 227234.
  • 8
    Weersma RK, van Dullemen HM, van der Steege G, et al. Review article: inflammatory bowel disease and genetics. Aliment Pharmacol Ther. 2007; 26( suppl 2): 5765.
  • 9
    Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 685695.
  • 10
    Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel disease. World J Gastroenterol. 2006; 12: 48194831.
  • 11
    Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010 [Epub ahead of print].
  • 12
    Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998; 338: 286290.
  • 13
    Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995; 90: 201205.
  • 14
    Stevens R, Oliver M, Brogan M, et al. Defective generation of tetanus-specific antibody producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology. 1985; 88: 18601866.
  • 15
    Melmed GY, Agarwal N, Frenck RW, et al. Immunosupression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2009; 105: 148154.
  • 16
    Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. J Pediatr Gastroenterol Nutr. 2007; 44: 431435.
  • 17
    Sands BE, Cuffari C, Katz J, et al. Guidelines for immunization in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 677692.
  • 18
    Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Gastroenterology. 2009; 3: 4791.
  • 19
    Mamula P, Markowitz JE, Piccolo DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 851856.
  • 20
    Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 444453.
  • 21
    Rybicka K, Romanowska M, Banaszkiewicz A, et al. Immunological response after vaccination against influenza A and B in children with inflammatory bowel disease. (abstract) ESPID Porto 2007.
  • 22
    IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41: 17.
  • 23
    Just M, Berger R. Reactogenicity and immunogenicity of inactivated hepatitis A vaccine. Vaccine. 1992; 10( suppl 1): S110S113.
  • 24
    Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994; 271: 13281334.
  • 25
    Ferreira CT, da Silveira TR, Vieira SM, et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003; 37: 258261.
  • 26
    Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999; 94: 16011604.
    Direct Link:
  • 27
    Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001; 36: 265269.
  • 28
    Dotan I, Vigodman S, Malter L, et al. Azathioprine/6-mercaptopurine therapy has no significant effect on cellular or humoral immune responses in patients with inflammatory bowel disease. Gastroenterology. 2007; 132: A51.
  • 29
    Elkayam O, Ablin J, Caspi D. Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Ann Rheum Dis. 2006; 65: 191194.
  • 30
    Nies K, Boyer R, Stevens R, et al. Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum. 1980; 23: 13431350.
  • 31
    Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 1001; 29: 25552557.
  • 32
    Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 1994; 21: 12031206.
  • 33
    Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer. 2004; 101: 635641.
  • 34
    Confavreux C, Suissa S, Saddier P, et al. Vaccination and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001; 344: 319326.
  • 35
    McMahon BJ, Beller M, Willimas J, et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996; 150: 733739.
  • 36
    Van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol. 1994; 44: 446451.